CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.

PloS One
Ranjan ChrisantharPer Eystein Lønning

Abstract

Chemoresistance is the main obstacle to cure in most malignant diseases. Anthracyclines are among the main drugs used for breast cancer therapy and in many other malignant conditions. Single parameter analysis or global gene expression profiles have failed to identify mechanisms causing in vivo resistance to anthracyclines. While we previously found TP53 mutations in the L2/L3 domains to be associated with drug resistance, some tumors harboring wild-type TP53 were also therapy resistant. The aim of this study was; 1) To explore alterations in the TP53 gene with respect to resistance to a regular dose epirubicin regimen (90 mg/m(2) every 3 week) in patients with primary, locally advanced breast cancer; 2) Identify critical mechanisms activating p53 in response to DNA damage in breast cancer; 3) Evaluate in vitro function of Chk2 and p14 proteins corresponding to identified mutations in the CHEK2 and p14((ARF)) genes; and 4) Explore potential CHEK2 or p14((ARF)) germline mutations with respect to family cancer incidence. Snap-frozen biopsies from 109 patients collected prior to epirubicin (as preoperative therapy were investigated for TP53, CHEK2 and p14((ARF)) mutations by sequencing the coding region and p14((ARF)) promoter met...Continue Reading

References

Mar 1, 1977·British Journal of Cancer·J L HaywardR D Rubens
Sep 23, 1998·Nature·S BatesK H Vousden
Mar 11, 1999·Current Opinion in Genetics & Development·N E Sharpless, R A DePinho
Nov 26, 1999·Proceedings of the National Academy of Sciences of the United States of America·N H ChehabT D Halazonetis
Oct 29, 2000·The Journal of Biological Chemistry·X WuJ Chen
Feb 13, 2001·Current Opinion in Genetics & Development·Y Shiloh
Feb 13, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M ChodorowskaD Kuklińska
Jun 16, 2001·Cancer Genetics and Cytogenetics·R I SkotheimR A Lothe
Dec 6, 2001·Nature Reviews. Molecular Cell Biology·J BartekJ Lukas
Feb 22, 2002·Oncogene·Alexandra SullivanTim Crook
Mar 5, 2002·British Journal of Cancer·A ReddyT Crook
Aug 3, 2002·Nature Reviews. Cancer·Karen H Vousden, Xin Lu
Aug 13, 2002·Proceedings of the National Academy of Sciences of the United States of America·Malte PetersTak W Mak
Sep 26, 2002·Proceedings of the National Academy of Sciences of the United States of America·Jonathan R PollackPatrick O Brown
Feb 8, 2003·Current Opinion in Genetics & Development·Soyoung Lee, Clemens A Schmitt
Mar 6, 2003·Human Mutation·J M Varley
Mar 8, 2003·The Lancet Oncology·Per Eystein Lønning
Mar 26, 2003·The Journal of Biological Chemistry·Prasad V JallepalliFred Bunz
Apr 30, 2003·Nature Cell Biology·Craig StevensNicholas B La Thangue
May 23, 2003·Cold Spring Harbor Symposia on Quantitative Biology·L B SchultzT D Halazonetis
Nov 7, 2003·Journal of Clinical Immunology·Jerry E Chipuk, Douglas R Green
Apr 23, 2004·Trends in Molecular Medicine·Per Eystein Lønning
Jul 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emilio AlbaUNKNOWN Spanish Breast Cancer Research Group
Sep 14, 2004·Oncogene·Vidar StaalesenPer Eystein Lønning
Dec 4, 2004·International Journal of Cancer. Journal International Du Cancer·Wing-pui TsangTim-tak Kwok

❮ Previous
Next ❯

Citations

Nov 22, 2014·Breast Cancer Research and Treatment·Werner PfeiferEvgeny N Imyanitov
Jan 16, 2009·Breast Cancer Research : BCR·Per Eystein Lønning
Jan 5, 2011·Breast Cancer Research : BCR·Per Eystein Lønning
May 6, 2011·Breast Cancer Research : BCR·Taru A MuranenHeli Nevanlinna
Aug 9, 2011·Hereditary Cancer in Clinical Practice·Evgeny N Imyanitov, Vladimir M Moiseyenko
Nov 8, 2012·Breast Cancer Research : BCR·Per E Lønning, Stian Knappskog
Nov 4, 2010·Current Opinion in Oncology·Magali Olivier, Philippe Taniere
Mar 16, 2012·Human Molecular Genetics·Wendy RoebMary-Claire King
Feb 9, 2012·Expert Opinion on Therapeutic Targets·Stian Knappskog, Per Eystein Lønning
Feb 26, 2011·International Journal of Cancer. Journal International Du Cancer·Darina GromykoJohan R Lillehaug
May 11, 2015·Journal of Cancer Research and Clinical Oncology·Mieke KriegeCaroline Seynaeve
Jan 19, 2010·Biochimica Et Biophysica Acta·Elisabet Ognedal BergePer Eystein Lønning
Jan 27, 2015·Archives of Toxicology·Daniel Speidel
May 5, 2012·PloS One·Stian KnappskogPer E Lønning
Aug 25, 2016·Hereditary Cancer in Clinical Practice·Aglaya G Iyevleva, Evgeny N Imyanitov
May 15, 2010·Molecular Oncology·Per E Lønning
Oct 7, 2016·Hereditary Cancer in Clinical Practice·Stian KnappskogPer E Lønning
Jan 25, 2019·JAMA Oncology·Saud H AlDubayanUNKNOWN Regeneron Genetics Center (RGC) Research Team
Dec 12, 2018·The Kaohsiung Journal of Medical Sciences·Soo Youn BaeSeok Jin Nam
Nov 30, 2019·Scientific Reports·Julie DutilAlvaro N Monteiro
May 6, 2019·International Journal of Cancer. Journal International Du Cancer·Petra KleiblovaZdenek Kleibl
Mar 19, 2016·International Journal of Cancer. Journal International Du Cancer·Inger Marie LøesPer Eystein Lønning
Oct 17, 2018·Breast Cancer Research : BCR·Elin BorgenBjørn Naume
Feb 19, 2017·Breast Cancer Research and Treatment·Synnøve YndestadHans Petter Eikesdal

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
biopsies
PCR
PCRs
immunoprecipitation
transfection
Kinase assay

Software Mentioned

Primer of Biostatistics system

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis